RGN-137
R-G-N one-thirty-seven
A fragment of thymosin beta-4 being researched for inflammatory bowel conditions and wound healing.
Also known as: Thymosin Beta-4 Fragment
Last reviewed: April 2026
What It Does
RGN-137 is a fragment of thymosin beta-4 developed specifically for gut healing. It's being studied for inflammatory bowel conditions where it may reduce inflammation and promote mucosal healing. Early clinical trials have shown promise.
Why People Take It
How It's Administered
Oral
Oral formulation for direct gut contact
Frequency
As studied in trials
Pain Level
○○○ None
Self-Administered
Yes — at home
Typical Range
Clinical trial dosing
What To Expect
Week 2–4
Inflammation reduction in clinical trial settings.
Month 2–3
Mucosal healing in responders.
Side Effects
Overall: Mild
Uncommon (0.1–1%)
GI discomfort
Paradoxical mild GI symptoms possible.
Who Should NOT Take This
• Pregnancy
• Limited clinical data
Drug Interactions
• Limited data
Pregnancy: Not studied. Avoid.
Clinical Details
Compare With Similar Peptides
Both target gut healing. BPC-157 is more broadly available and better studied. RGN-137 is in formal clinical trials.
Open Full Comparison Tool →Frequently Asked Questions
This compound is in early research stages. We do not currently offer it.
Looking for something similar? See what we offer for Gut Health.
This compound is in early research stages. It has not been FDA-approved and may not be available through compounding pharmacies. The information below is for educational purposes only. Do not attempt to self-administer research compounds.